-
1 Comment
HTG Molecular Diagnostics, Inc is currently in a long term uptrend where the price is trading 4.3% above its 200 day moving average.
From a valuation standpoint, the stock is 99.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.1.
HTG Molecular Diagnostics, Inc's total revenue sank by 46.2% to $3M since the same quarter in the previous year.
Its net income has increased by 99.9% to $-4K since the same quarter in the previous year.
Finally, its free cash flow grew by 14.8% to $-4M since the same quarter in the previous year.
Based on the above factors, HTG Molecular Diagnostics, Inc gets an overall score of 4/5.
Industry | Healthcare Equipment & Supplies |
---|---|
CurrencyCode | USD |
ISIN | US40434H2031 |
Exchange | NASDAQ |
Sector | Healthcare |
Market Cap | 1M |
---|---|
PE Ratio | None |
Target Price | 6 |
Dividend Yield | 0.0% |
Beta | 0.99 |
HTG Molecular Diagnostics, Inc. a life sciences company, focuses on the precision medicine. The company offers instruments; consumables; and software that automate sample processing and profiles various molecular targets. Its marketed molecular profiling panels include HTG Transcriptome Panel; HTG EdgeSeq precision immuno-oncology panel; HTG EdgeSeq miRNA whole-transcriptome assay; HTG EdgeSeq DLBCL cell of origin assay EU; HTG EdgeSeq Oncology Biomarker Panel; HTG immune response panel; and HTG mouse mRNA tumor response panel. The company distributes its instruments and consumables directly in the United States and Europe; and through distributors in parts of Europe and internationally. It serves biopharmaceutical companies, academic research centers, and molecular testing laboratories. The company was formerly known as HTG, Inc. and changed its name to HTG Molecular Diagnostics, Inc. in March 2011. HTG Molecular Diagnostics, Inc. was incorporated in 1997 and is based in Tucson, Arizona. On June 5, 2023, HTG Molecular Diagnostics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for HTGM using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025